- Home
- INBS vs NXTS Comparison
INBS vs NXTS Comparison
Compare INBS & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBS | NXTS |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | Israel |
| Employees | N/A | 9 |
| Industry | Medical Specialities | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.3M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | INBS | NXTS |
|---|---|---|
| Price | $1.60 | $1.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 72.0K | 64.1K |
| Earning Date | 05-08-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,980,484.00 | N/A |
| Revenue This Year | $778.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.55 |
| 52 Week High | $24.90 | $23.80 |
Technical Indicators
Market Signals| Indicator | INBS | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 24.56 | 32.77 |
| Support Level | $0.59 | $0.55 |
| Resistance Level | $2.45 | $5.31 |
| Average True Range (ATR) | 0.19 | 0.29 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 8.79 | 3.39 |
Price Performance
Historical ComparisonAbout INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.